LEXINGTON – US firm Tepha, Inc., which sells medical devices derived from resorbable, biodegradable, polyhydroxyalkanoate (PHA) polymers has altered its existing agreement with its licensor Metabolix that will see it pay US$2 million to Metabolix in order to waive future royalties under its existing license agreement.
PHAs are linear polyesters produced naturally by bacterial fermentation of sugar or lipids. Absorbable polyester fibers, braids and surgical meshes with prolonged strength retention have been developed using PHA technology for medical textiles due to its biocompatibility.
Metabolix is currently evaluating strategic alternatives for its specialty biopolymers business and Yield10 crop science program and is engaged in ongoing efforts to secure additional funding for its strategic review process and operations.
